IMRX

Immuneering Corporation
CAPPED RATING

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Immuneering Corporation (IMRX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.3
EV / EBITDA -1.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -27.1%
Price Return 12M -45.1%
Catalyst Signal 0.00
Market Cap $245.5M
TTM Revenue N/A
Price / Sales N/A
ROE -33.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D (1.3) C+ (2.6) D+ (1.8) C+ (2.6) C (2.2)
2026-11-05 C+ (2.5) D+ (1.8) C+ (2.6) C- (2.1) C+ (2.7) C (2.3)
2026-10-29 C+ (2.5) D+ (1.6) C+ (2.6) C (2.2) C+ (2.7) C (2.3)
2026-10-22 C+ (2.5) D+ (1.5) C+ (2.6) C- (2.1) C+ (2.6) C (2.3)
2026-10-15 C+ (2.5) D+ (1.5) C+ (2.6) D+ (1.8) C+ (2.6) C (2.2)
Page 1 of 4